Phase 2 Trial Shows CDR132L Well Tolerated but Ineffective for Post-MI Heart Failure
A randomized, double-blind, placebo-controlled phase 2 trial published in Nature Medicine evaluated the efficacy and safety of CDR132L, an antisense oligonucleotide inhibitor of microRNA-132, in patients with reduced left ventricular ejection fraction following myocardial infarction. The HF-REVERT study involved 294 patients who received either CDR132L (5 mg/kg or 10 mg/kg) or placebo alongside standard guideline-directed therapy. Results presented at the 2026 ESC Heart Failure Congress indicated that while CDR132L was well tolerated with no significant toxicity signals, it failed to demonstrate a statistically significant improvement in primary endpoints, such as left ventricular end-systolic volume index, or secondary measures like ejection fraction compared to placebo. Although the overall trial did not meet its primary efficacy goals, exploratory analyses suggested potential benefits for patients with advanced adverse remodeling at baseline. These findings highlight the challenges in translating preclinical success to human trials for cardiac remodeling therapies but support further investigation of CDR132L in specific chronic heart failure populations.
Wire timeline
Phase 2 Trial Shows CDR132L Well Tolerated but Ineffective for Post-MI Heart Failure
A randomized, double-blind, placebo-controlled phase 2 trial published in Nature Medicine evaluated the efficacy and safety of CDR132L, an antisense oligonucleotide inhibitor of microRNA-132, in patients with reduced left ventricular ejection fraction following myocardial infarction. The HF-REVERT study involved 294 patients who received either CDR132L (5 mg/kg or 10 mg/kg) or placebo alongside standard guideline-directed therapy. Results presented at the 2026 ESC Heart Failure Congress indicated that while CDR132L was well tolerated with no significant toxicity signals, it failed to demonstrate a statistically significant improvement in primary endpoints, such as left ventricular end-systolic volume index, or secondary measures like ejection fraction compared to placebo. Although the overall trial did not meet its primary efficacy goals, exploratory analyses suggested potential benefits for patients with advanced adverse remodeling at baseline. These findings highlight the challenges in translating preclinical success to human trials for cardiac remodeling therapies but support further investigation of CDR132L in specific chronic heart failure populations.
Nature Medicine